Irritable Bowel Syndrome Treatment Market is estimated to surge ahead at a CAGR of 8.3% to reach US$ 8.3 Bn by the end of 2033 | PMR

Irritable Bowel Syndrome (IBS) is a chronic disorder that affects the large intestine and causes symptoms such as abdominal pain, bloating, constipation and diarrhea. The treatment for IBS is mainly based on symptom management and dietary changes, and medications such as antispasmodics, laxatives, and antidepressants are also used to manage the symptoms of IBS.

Worldwide revenue from the irritable bowel syndrome treatment market stands at US$ 3.4 Bn in 2022, with the global market estimated to surge ahead at a CAGR value of 8.3% to reach a valuation of US$ 8.3 Bn by the end of 2033.

Request For Free Sample Report of "Irritable Bowel Syndrome Treatment Market"@ https://www.persistencemarketresearch.com/samples/9938

The global irritable bowel syndrome treatment market is expected to grow at a significant rate during the forecast period, driven by factors such as increasing prevalence of irritable bowel syndrome, growing awareness about the disease, and the increasing availability of treatment options.

The market is segmented based on drug class, distribution channel, and region. On the basis of drug class, the market is segmented into antispasmodics, laxatives, antidepressants, and others. On the basis of distribution channel, the market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

 Companies

Pfizer, Inc.
Takeda Pharmaceutical Company Limited
Abbott Laboratories
Novartis AG
AstraZeneca PLC
Ironwood Pharmaceuticals Inc. and Allergan Plc
Bausch Health Companies Inc.
GlaxoSmithKline, Plc.
Lexicon Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.

 Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/9938

The major players operating in the irritable bowel syndrome treatment market include AstraZeneca, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and others. These players have adopted various strategies, such as partnerships, collaborations, and new product launches, to increase their share in the market.

In conclusion, the global irritable bowel syndrome treatment market is expected to grow at a significant rate during the forecast period, driven by factors such as increasing prevalence of irritable bowel syndrome, growing awareness about the disease, and the increasing availability of treatment options. The major players operating in the market are focusing on strategies such as partnerships, collaborations, and new product launches to increase their share in the market. Competitive Landscape

To improve their product lines across the globe, the leading manufacturers are developing technologically advanced products. The major competitors in the irritable bowel syndrome treatment industry are involved in several consolidation activities such as product launches and mergers and acquisitions.

For instance:

In March 2021, Abbott and Nutrition Society of India partenered together in order to raise awareness amongst patients suffering from GI conditions by introducing India-specific clinical dietary recommendations. GI conditions range from functional constipation to peptic ulcers, chronic pancreatitis, and irritable bowel syndrome.
In March 2021, Bausch Health Companies Inc. launched GastroHub for advanced practice providers. It is an educational website designed with information related to treatment of IBS-D as well as HE for nurse practitioners and physician assistants.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/9938

Key Segments Covered in Irritable Bowel Syndrome Treatment Industry Research

By Product:

Fiber Supplements
Anti-Diarrheal
Anticholinergic and Antispasmodic
Antidepressant
Antibiotics
Alosetron
Lubiprostone
Linaclotide
NHE3

By Indication:

Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome with Diarrhoea
Irritable Bowel Syndrome with alternating Constipation and Diarrhoea

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies and Stores
Hypermarkets and Supermarkets

 For More Premium Insights, Check out the Link:

Libya Dialysis Machines market - https://www.globenewswire.com/en/news-release/2022/09/14/2515578/0/en/Libya-Dialysis-Machines-Market-reach-a-market-size-of-US-966-2-Mn-by-the-end-of-2032-Persistence-Market-Research.html

OTC Scar Treatment market - https://www.globenewswire.com/en/news-release/2022/09/13/2515077/0/en/OTC-Scar-Treatment-Market-estimated-to-move-ahead-at-a-value-CAGR-of-3-8-by-the-end-of-2032-GNW.html

High Flow Oxygen Therapy Devices market - https://www.globenewswire.com/en/news-release/2022/09/13/2514562/0/en/High-Flow-Oxygen-Therapy-Devices-Market-reach-a-size-of-US-1-4-Bn-by-the-end-of-2032-GNW.html

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.